Document is current
Any future updates will be listed below
-
Authors
Dierig, A https://orcid.org/0000-0001-6505-8797
Hoelscher, M
Schultz, S
Hoffmann, L
Jarchow-MacDonald, A
Svensson, EM
Te Brake, L
Aarnoutse, R
Boeree, M
McHugh, TD
Wildner, LM
Gong, X
Phillips, PPJ
Minja, LT
Ntinginya, N
Mpagama, S
Liyoyo, A
Wallis, RS
Sebe, M
Mhimbira, FA
Mbeya, B
Rassool, M
Geiter, L
Cho, YL
Heinrich, N
-
Funding
Funding for this research was provided by:
LegoChem Biosciences, Inc
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 1 September 2022
Accepted: 5 May 2023
First Online: 6 June 2023
Declarations
:
: This study protocol was approved by the Ethic committee of the Ludwig-Maximilians-University of Munich, Germany and by applicable ethics committees of the trial sites. These include:South African Health Products and Regulatory Authority, Arcadia, South AfricaHuman Research Ethics committee, University of the Witwatersrand (Ref 200910B)Medical Research Coordinating Committee Tanzania (Ref NIMR/HQ/R.8a/Vol.IX/3649)Mbeya Medical Research and Ethics review committee, Mbeya, Tanzania (Ref SZEC-2439/R.A./V.1/105)Institutional Review Board, Ifakara Health Institute, Dar es Salaam, Tanzania (Ref IHI/IRB/AMM/ No: 11-2021)Kilimanjaro Christian Medical College Research Ethics and Review Committee (CRERC), Moshi, TanzaniaWritten informed consent will be obtained from each participant or its legal guardian. The informed consent is available from the corresponding author on request.
: “Informed consent forms” of the study may be provided by the corresponding author upon reasonable request.
: All authors except LG and YLC report receiving research funding from LegoChem Biosciences to their institutions. LG receives compensation as a consultant. YLC is an employee of LegoChem Biosciences. Further, the authors would like to report receiving delamanid (Deltyba®) free of charge, from Otsuka Novel Products GmbH.
